The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
about
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyAntitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.
P2860
The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@en
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@nl
type
label
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@en
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@nl
prefLabel
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@en
The anti-lymphoma activity of ...... ation with anti-CD20 antibody.
@nl
P2093
P2860
P1433
P1476
The anti-lymphoma activity of ...... nation with anti-CD20 antibody
@en
P2093
Aimable Nahimana
Bernard Sordat
Dominique Aubry
Michel A Duchosal
Pierre Vogel
Somi R Majjigapu
P2860
P304
P356
10.3109/10428194.2013.869325
P577
2014-01-24T00:00:00Z